165 related articles for article (PubMed ID: 37272932)
1. A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis.
König P; Zhulenko R; Suparman E; Hoffmeister H; Bückreiß N; Ott I; Bendas G
Cancer Chemother Pharmacol; 2023 Jul; 92(1):57-69. PubMed ID: 37272932
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells.
Wantoch von Rekowski K; König P; Henze S; Schlesinger M; Zawierucha P; Januchowski R; Bendas G
Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31779287
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.
Marzano C; Gandin V; Folda A; Scutari G; Bindoli A; Rigobello MP
Free Radic Biol Med; 2007 Mar; 42(6):872-81. PubMed ID: 17320769
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties.
Landini I; Massai L; Cirri D; Gamberi T; Paoli P; Messori L; Mini E; Nobili S
J Inorg Biochem; 2020 Jul; 208():111079. PubMed ID: 32497830
[TBL] [Abstract][Full Text] [Related]
5. A TrxR inhibiting gold(I) NHC complex induces apoptosis through ASK1-p38-MAPK signaling in pancreatic cancer cells.
Cheng X; Holenya P; Can S; Alborzinia H; Rubbiani R; Ott I; Wölfl S
Mol Cancer; 2014 Sep; 13():221. PubMed ID: 25253202
[TBL] [Abstract][Full Text] [Related]
6. Insight into Cisplatin-Resistance Signaling of W1 Ovarian Cancer Cells Emerges mTOR and HSP27 as Targets for Sensitization Strategies.
Wantoch von Rekowski K; König P; Henze S; Schlesinger M; Zawierucha P; Januchowski R; Bendas G
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287446
[TBL] [Abstract][Full Text] [Related]
7. The effects of two gold-N-heterocyclic carbene (NHC) complexes in ovarian cancer cells: a redox proteomic study.
Massai L; Messori L; Carpentieri A; Amoresano A; Melchiorre C; Fiaschi T; Modesti A; Gamberi T; Magherini F
Cancer Chemother Pharmacol; 2022 Jun; 89(6):809-823. PubMed ID: 35543764
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
9. The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.
Mueller T; Pfankuchen DB; Wantoch von Rekowski K; Schlesinger M; Reipsch F; Bendas G
Molecules; 2017 May; 22(5):. PubMed ID: 28467373
[TBL] [Abstract][Full Text] [Related]
10. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: a comparative proteomic study.
Magherini F; Fiaschi T; Valocchia E; Becatti M; Pratesi A; Marzo T; Massai L; Gabbiani C; Landini I; Nobili S; Mini E; Messori L; Modesti A; Gamberi T
Oncotarget; 2018 Jun; 9(46):28042-28068. PubMed ID: 29963261
[TBL] [Abstract][Full Text] [Related]
12. Combined use of cisplatin plus natural killer cells overcomes immunoresistance of cisplatin resistant ovarian cancer.
Choi SH; Jung D; Kim KY; An HJ; Park KS
Biochem Biophys Res Commun; 2021 Jul; 563():40-46. PubMed ID: 34058473
[TBL] [Abstract][Full Text] [Related]
13. Overcome of Cisplatin Resistance in Ovarian Cancer by Combination of Low-intensity Ultrasound and Cisplatin.
Kip B; Aydin O
Curr Drug Deliv; 2023; 20(9):1380-1390. PubMed ID: 35761504
[TBL] [Abstract][Full Text] [Related]
14. How liposomal Cisplatin overcomes chemoresistance in ovarian tumour cells.
Stölting DP; Borrmann M; Koch M; Wiese M; Royer HD; Bendas G
Anticancer Res; 2014 Jan; 34(1):525-30. PubMed ID: 24403511
[TBL] [Abstract][Full Text] [Related]
15. Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells.
Guo J; Satoh K; Tabata S; Mori M; Tomita M; Soga T
BMC Cancer; 2021 Feb; 21(1):174. PubMed ID: 33596851
[TBL] [Abstract][Full Text] [Related]
16. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.
Bao L; Wu J; Dodson M; Rojo de la Vega EM; Ning Y; Zhang Z; Yao M; Zhang DD; Xu C; Yi X
Mol Carcinog; 2017 Jun; 56(6):1543-1553. PubMed ID: 28112439
[TBL] [Abstract][Full Text] [Related]
17. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
Rao YM; Shi HR; Ji M; Chen CH
J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):567-572. PubMed ID: 23904379
[TBL] [Abstract][Full Text] [Related]
18. On the path to gold: Monoanionic Au bisdithiolate complexes with antimicrobial and antitumor activities.
Sousa SA; Leitão JH; Silva RAL; Belo D; Santos IC; Guerreiro JF; Martins M; Fontinha D; Prudêncio M; Almeida M; Lorcy D; Marques F
J Inorg Biochem; 2020 Jan; 202():110904. PubMed ID: 31671298
[TBL] [Abstract][Full Text] [Related]
19. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
20. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
